Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;30(9):2661-2668.
doi: 10.1111/ene.15890. Epub 2023 Jun 6.

Development of anxiety in early Parkinson's disease: A clinical and biomarker study

Hanyuying Wang  1 , Yibo Zhao  1   2 , Anette Schrag  1
Affiliations

Development of anxiety in early Parkinson's disease: A clinical and biomarker study

Hanyuying Wang et al. Eur J Neurol. 2023 Sep.

Abstract

Background: Anxiety affects approximately 40% of Parkinson's disease (PD) patients. However, little is known about its predictors and development over time.

Objective: To identify the clinical factors and biomarkers associated with development of anxiety in patients with newly diagnosed PD, and to test which risk factors predict increases in anxiety over time.

Methods: Data from the Parkinson's Progression Markers Initiative (PPMI) were utilized. The primary outcome was the State-Trait Anxiety Inventory (STAI). Covariates were demographics, motor and non-motor symptoms, cognitive functions, dopamine transporter imaging data, and cerebrospinal fluid (CSF) biomarkers. We examined the association of risk factors at baseline and over 4 years with changes in anxiety scores over time.

Results: A total of 252 patients met the inclusion criteria (mean age: 61.36 years, SD 9.53). At year 4, 42 patients had developed anxiety. Baseline predictors of increase in anxiety scores were greater autonomic dysfunction, dysexecutive function, CSF t-tau levels, excessive daytime sleepiness, and lower olfactory function scores but not motor scores. Over 4 years, change in anxiety scores correlated with deterioration in overall cognitive function, excessive daytime sleepiness, as well as depression and disability, and to a lesser degree worsening of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor scores and caudate dopaminergic uptake changes.

Conclusions: These findings suggest that development of anxiety in PD is not primarily based on a dopaminergic deficit in the basal ganglia but related to non-dopaminergic or extrastriatal pathology. Early dysexecutive function predicts development of anxiety but increase in anxiety levels correlates most strongly with more global cognitive decline.

Keywords: Parkinson's disease; anxiety; biomarkers; clinical features; early stage; prospective study.

PubMed Disclaimer

References

REFERENCES

    1. Deane KH, Flaherty H, Daley DJ, et al. Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease. BMJ Open. 2014;4(12):e006434.
    1. Burn DJ, Landau S, Hindle JV, et al. Parkinson's disease motor subtypes and mood. Mov Disord. 2012;27(3):379-386.
    1. Ujvári B, Pytel B, Márton Z, et al. Neurodegeneration in the centrally-projecting Edinger-Westphal nucleus contributes to the non-motor symptoms of Parkinson's disease in the rat. J Neuroinflammation. 2022;19(1):31. doi:10.1186/s12974-022-02399-w
    1. Brown RG, Landau S, Hindle JV, et al. Depression and anxiety related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011;82(7):803-809.
    1. Schrag A, Taddei RN. Depression and anxiety in Parkinson's disease. Int Rev Neurobiol. 2017;133:623-655.

Publication types

MeSH terms